XRB vs. SLB in Jail and at Re-entry: Pilot, Proof of Concept
Status:
Completed
Trial end date:
2020-05-04
Target enrollment:
Participant gender:
Summary
This is a pilot proof-of-concept randomized controlled trial, open-label and unblinded,
examining the feasibility and acceptability of Buprenorphine extended-release vs. daily
sublingual buprenorphine-naloxone for the treatment of opioid use disorder in jail and at
community re-entry.
Phase:
Phase 4
Details
Lead Sponsor:
New York University School of Medicine NYU Langone Health
Collaborator:
NYC Health + Hospitals
Treatments:
Buprenorphine Buprenorphine, Naloxone Drug Combination Naloxone